颞部肌肉质量变化与肢端肥大症治疗之间的关联。

IF 1.6 4区医学 Q4 CELL BIOLOGY

Growth Hormone & Igf Research Pub Date : 2024-10-10 DOI:10.1016/j.ghir.2024.101626

Serdar Sahin , Ahmet Oz , Burcu Saglamer , Cem Sulu , Ahmet Numan Demir , Lala Soltanova , Mustafa Duru , Serdar Arslan , Hande Mefkure Ozkaya , Osman Kizilkilic , Necmettin Tanriover , Pinar Kadioglu

{"title":"颞部肌肉质量变化与肢端肥大症治疗之间的关联。","authors":"Serdar Sahin , Ahmet Oz , Burcu Saglamer , Cem Sulu , Ahmet Numan Demir , Lala Soltanova , Mustafa Duru , Serdar Arslan , Hande Mefkure Ozkaya , Osman Kizilkilic , Necmettin Tanriover , Pinar Kadioglu","doi":"10.1016/j.ghir.2024.101626","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>We aimed to evaluate the relationship between temporal muscle thickness and GH/IGF-1 elevation and the effect of acromegaly treatment on temporal muscle thickness.</div></div><div><h3>Methods</h3><div>Patients with acromegaly and healthy controls were included in the study. While laboratory parameters, clinical findings and temporal muscle thickness of acromegaly patients at the time of diagnosis and one year after treatment were evaluated, laboratory parameters and temporal muscle thickness of healthy controls were evaluated only during the period when they were included in the study. Temporal muscle thickness was measured using pituitary MRI. Temporal muscle thickness of patients with acromegaly was compared with healthy controls. We also evaluated how temporal muscle thickness changes with treatment in patients with acromegaly and the association between laboratory parameters and temporal muscle thickness.</div></div><div><h3>Results</h3><div>In patients with acromegaly, measurements of left, right, and mean temporal muscle thickness at the time of diagnosis were found to be significantly higher than those of healthy controls' measurements at the time of their inclusion in the study (<em>p</em> = 0.007, <em>p</em> = 0.014 and <em>p</em> = 0.018, respectively). However, no significant difference was found when comparing the temporal muscle thickness of the 1st year of acromegaly treatment with the temporal muscle thickness of healthy controls at the time of their inclusion in the study (<em>p</em> = 0.155, <em>p</em> = 0.189, <em>p</em> = 0.198, respectively). In addition, a significant decrease was detected in the left, right and mean temporal muscle thicknesses of patients with acromegaly before and after treatment. While the temporal muscle thickness at the time of diagnosis was thicker in patients with acromegaly receiving surgical + medical treatment than in patients receiving exclusively surgical treatment, statistical significance was only found in the left temporal muscle thickness (<em>p</em> = 0.042).</div></div><div><h3>Conclusion</h3><div>Temporal muscle thickness was found to be associated with treatment modalities in patients with acromegaly.</div></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"79 ","pages":"Article 101626"},"PeriodicalIF":1.6000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The association between change in temporal muscle mass and treatment of acromegaly\",\"authors\":\"Serdar Sahin , Ahmet Oz , Burcu Saglamer , Cem Sulu , Ahmet Numan Demir , Lala Soltanova , Mustafa Duru , Serdar Arslan , Hande Mefkure Ozkaya , Osman Kizilkilic , Necmettin Tanriover , Pinar Kadioglu\",\"doi\":\"10.1016/j.ghir.2024.101626\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>We aimed to evaluate the relationship between temporal muscle thickness and GH/IGF-1 elevation and the effect of acromegaly treatment on temporal muscle thickness.</div></div><div><h3>Methods</h3><div>Patients with acromegaly and healthy controls were included in the study. While laboratory parameters, clinical findings and temporal muscle thickness of acromegaly patients at the time of diagnosis and one year after treatment were evaluated, laboratory parameters and temporal muscle thickness of healthy controls were evaluated only during the period when they were included in the study. Temporal muscle thickness was measured using pituitary MRI. Temporal muscle thickness of patients with acromegaly was compared with healthy controls. We also evaluated how temporal muscle thickness changes with treatment in patients with acromegaly and the association between laboratory parameters and temporal muscle thickness.</div></div><div><h3>Results</h3><div>In patients with acromegaly, measurements of left, right, and mean temporal muscle thickness at the time of diagnosis were found to be significantly higher than those of healthy controls' measurements at the time of their inclusion in the study (<em>p</em> = 0.007, <em>p</em> = 0.014 and <em>p</em> = 0.018, respectively). However, no significant difference was found when comparing the temporal muscle thickness of the 1st year of acromegaly treatment with the temporal muscle thickness of healthy controls at the time of their inclusion in the study (<em>p</em> = 0.155, <em>p</em> = 0.189, <em>p</em> = 0.198, respectively). In addition, a significant decrease was detected in the left, right and mean temporal muscle thicknesses of patients with acromegaly before and after treatment. While the temporal muscle thickness at the time of diagnosis was thicker in patients with acromegaly receiving surgical + medical treatment than in patients receiving exclusively surgical treatment, statistical significance was only found in the left temporal muscle thickness (<em>p</em> = 0.042).</div></div><div><h3>Conclusion</h3><div>Temporal muscle thickness was found to be associated with treatment modalities in patients with acromegaly.</div></div>\",\"PeriodicalId\":12803,\"journal\":{\"name\":\"Growth Hormone & Igf Research\",\"volume\":\"79 \",\"pages\":\"Article 101626\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Growth Hormone & Igf Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S109663742400056X\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Growth Hormone & Igf Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S109663742400056X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：我们旨在评估颞肌厚度与 GH/IGF-1 升高之间的关系，以及肢端肥大症治疗对颞肌厚度的影响：研究对象包括肢端肥大症患者和健康对照组。在对肢端肥大症患者诊断时和治疗一年后的实验室参数、临床表现和颞肌厚度进行评估的同时，仅在健康对照组参与研究期间对其实验室参数和颞肌厚度进行评估。颞肌厚度通过垂体磁共振成像进行测量。肢端肥大症患者的颞肌厚度与健康对照组进行了比较。我们还评估了肢端肥大症患者颞肌厚度随治疗的变化情况，以及实验室参数与颞肌厚度之间的关联：结果：发现肢端肥大症患者确诊时的左侧、右侧和平均颞肌厚度测量值明显高于健康对照组纳入研究时的测量值（分别为 p = 0.007、p = 0.014 和 p = 0.018）。然而，在将肢端肥大症治疗第一年的颞肌厚度与健康对照组纳入研究时的颞肌厚度进行比较时，并未发现明显差异（分别为 p = 0.155、p = 0.189 和 p = 0.198）。此外，肢端肥大症患者在治疗前后的左侧、右侧和平均颞肌厚度均有明显下降。虽然接受手术+药物治疗的肢端肥大症患者在确诊时的颞肌厚度比只接受手术治疗的患者厚，但只有左侧颞肌厚度具有统计学意义（p = 0.042）：结论：颞肌厚度与肢端肥大症患者的治疗方式有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The association between change in temporal muscle mass and treatment of acromegaly

Purpose

We aimed to evaluate the relationship between temporal muscle thickness and GH/IGF-1 elevation and the effect of acromegaly treatment on temporal muscle thickness.

Methods

Patients with acromegaly and healthy controls were included in the study. While laboratory parameters, clinical findings and temporal muscle thickness of acromegaly patients at the time of diagnosis and one year after treatment were evaluated, laboratory parameters and temporal muscle thickness of healthy controls were evaluated only during the period when they were included in the study. Temporal muscle thickness was measured using pituitary MRI. Temporal muscle thickness of patients with acromegaly was compared with healthy controls. We also evaluated how temporal muscle thickness changes with treatment in patients with acromegaly and the association between laboratory parameters and temporal muscle thickness.

Results

In patients with acromegaly, measurements of left, right, and mean temporal muscle thickness at the time of diagnosis were found to be significantly higher than those of healthy controls' measurements at the time of their inclusion in the study (p = 0.007, p = 0.014 and p = 0.018, respectively). However, no significant difference was found when comparing the temporal muscle thickness of the 1st year of acromegaly treatment with the temporal muscle thickness of healthy controls at the time of their inclusion in the study (p = 0.155, p = 0.189, p = 0.198, respectively). In addition, a significant decrease was detected in the left, right and mean temporal muscle thicknesses of patients with acromegaly before and after treatment. While the temporal muscle thickness at the time of diagnosis was thicker in patients with acromegaly receiving surgical + medical treatment than in patients receiving exclusively surgical treatment, statistical significance was only found in the left temporal muscle thickness (p = 0.042).

Conclusion

Temporal muscle thickness was found to be associated with treatment modalities in patients with acromegaly.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Growth Hormone & Igf Research 医学-内分泌学与代谢

CiteScore

3.30

自引率

0.00%

发文量

审稿时长

57 days

期刊介绍： Growth Hormone & IGF Research is a forum for research on the regulation of growth and metabolism in humans, animals, tissues and cells. It publishes articles on all aspects of growth-promoting and growth-inhibiting hormones and factors, with particular emphasis on insulin-like growth factors (IGFs) and growth hormone. This reflects the increasing importance of growth hormone and IGFs in clinical medicine and in the treatment of diseases.